Sano is collaborating with an integrated research organisation to identify, engage, and genetically test patients with metabolic dysfunction-associated steatohepatitis (MASH), a condition often asymptomatic in its early stages.

Sano's approach includes developing a user-friendly online platform for smooth participant engagement, providing site-specific training, ensuring eligibility verification, offering free genetic testing with counselling, and distributing personalised content to keep participants engaged in future trials. This proactive, tailored strategy contrasts with traditional, reactive MASH treatment models, utilising the latest in genetics and bioinformatics to improve disease management and trial outcomes.

Download the case study to learn more and stay updated as this programme develops!